β受体阻滞剂治疗慢性重症充血性心力衰竭的临床疗效分析

Clinical efficacy of combined beta blocker in the treatment of chronic severe congestive heart failure

目的探讨在常规治疗基础上联合使用β受体阻滞剂对慢性重症充血性心力衰竭的临床治疗效果。方法选取温州医科大学定理临床学院于2015年11月～2017年1月期间收治的78例慢性重症充血性心力衰竭患者作为研究对象,随机均分为研究组（n=39）和对照组（n=39）。对照组慢性重症充血性心力衰竭患者给予常规治疗,研究组在常规治疗基础上加用β受体阻滞剂美托洛尔。记录2组治疗前后DBP、SBP、LVEF、LVEDD等指标变化情况及不良反应发生率。结果经分析可知2组治疗前DBP、SBP、LVEF、LVEDD等指标对比并无显著差异;经治疗后研究组DBP、SBP、LVEDD等指标下降幅度以及LVEF上升幅度均优于对照组,数据对比差异有统计学意义（P〈0.05）;经不同药物方案治疗期间研究组慢性重症充血性心力衰竭患者不良反应发生率与对照组对比并无显著差异。结论应用常规方案治疗基础上加用β受体阻滞剂美托洛尔可显著提高慢性重症充血性心力衰竭患者临床疗效,有利于保障其预后、生活质量。

Objective To investigate the clinical efficacy of combined use of beta blocker in the treatment of chronic severe congestive heart failure（CHF）.Methods 78 patients with severe chronic congestive heart failure in patients from November 2015 to January 2017 were randomly divided into study group（n=39） and control group（n=39）.The control group was treated with routine treatment of chronic severe congestive heart failure,and the study group was treated with beta blocker metoprolol on the basis of routine treatment.The changes of DBP,SBP,LVEF,LVEDD and the incidence of adverse reactions were recorded before and after treatment in two groups.Results After the analysis of the two groups before treatment,DBP,SBP,LVEF,LVEDD and other indicators compared no significant difference;after the treatment of DBP,SBP,LVEDD group index decline and increase of LVEF were better than the control group,comparing the data with significant difference（P〈0.05）;drug therapy in the treatment of severe chronic group occurred during the study period the rate of adverse reactions in patients with congestive heart failure and there is no significant difference compared with control group.Conclusion The use of routine regimen based on the use of beta blocker metoprolol can significantly improve the clinical efficacy of patients with chronic severe congestive heart failure,and is conducive to the protection of their prognosis and quality of life.